Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03936374 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

A Phase 1 study of Healthy, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT03936374: Completed Phase 1 study of Healthy, sponsored by Bristol-Myers Squibb.

NCT03936374 is a Phase 1 study of Healthy that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03936374, a Phase 1 study of Healthy, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the effect of multiple dose administrations of Omeprazole on the pharmacokinetics of BMS-986205.

Conditions Studied

Interventions

  • DRUG BMS-986205
  • DRUG omeprazole

Study Locations (1)

Texas

  • PPD Phase I Clinic - Austin

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2019-05-08
Est. Completion 2019-07-20
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT03936374 record still lists

NCT03936374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which BMS-986205 is the first listed.

NCT03936374 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03936374 about?

NCT03936374 is a clinical study titled "A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants". The purpose of this study is to assess the effect of multiple dose administrations of Omeprazole on the pharmacokinetics of BMS-986205.

What is the current status of trial NCT03936374?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-05-08. Estimated completion is 2019-07-20.

What conditions does trial NCT03936374 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03936374?

The interventions under investigation include: BMS-986205 (DRUG), omeprazole (DRUG).

Who is sponsoring clinical trial NCT03936374?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03936374 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03936374's enrollment target sits among peer trials

16 936th of 1090 higher than 137 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03936374, the US trial registry maintained by the National Library of Medicine. NCT03936374 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.